A Risk-scoring Model for Predicting Post-recurrence Survival in Patients With Endometrial Carcinoma |
| |
| Affiliation: | 1. Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland;2. Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland;1. Northern Ireland Cancer Centre, Belfast, United Kingdom;2. University College London Hospitals NHS Foundation Trust, London, United Kingdom;3. The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom;4. The Institute of Cancer Research, London, United Kingdom;5. Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, United Kingdom;1. University Hospitals Sussex NHS Foundation Trust, West Sussex, United Kingdom;2. Cancer Centre, Addenbrooke''s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom;3. Department of Oncology, The Queen Elizabeth Hospital King''s Lynn, King''s Lynn, United Kingdom;1. Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, India;2. Department of Radiation Oncology, Foundation Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain;3. U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy;4. Otorinolaringology Division, Azienda Ospedaliero Universitaria, Sassari, Italy;5. Department of Medicine, Surgery and Pharmacy, Università degli studi di Sassari, Sassari, Italy;7. Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, Rome, Italy;1. Churchill Hospital, Oxford University NHS Trust, Oxford, UK;2. Velindre Cancer Centre, Cardiff, UK;1. Private Academic Consultant, Samraong, Cambodia;2. Chandigarh University, Punjab, India;3. Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria |
| |
| Abstract: | AimsThe survival time of patients with recurrent endometrial carcinoma is generally short. However, considerable interindividual variation exists. We developed a risk-scoring model for predicting post-recurrence survival in patients with endometrial carcinoma.Materials and methodsPatients with endometrial carcinoma treated at a single institution between 2007 and 2013 were identified. Pearson chi-squared analyses were used to compute odds ratios for the associations between risk factors and short survival after cancer recurrence. The results for biochemical analyses represented values at diagnosis of disease recurrence or values at initial diagnosis for those patients who had a primary refractory disease. Logistic regression models were constructed for the identification of variables that independently predict short post-recurrence survival. The models were used to assign points based on odds ratios for risk factors and risk scores were derived.ResultsIn total, 236 patients with recurrent endometrial carcinoma were included in the study. Based on overall survival analysis, 12 months was selected as the cut-off for short post-recurrence survival. Factors associated with short post-recurrence survival were platelet count, serum CA125 concentration and progression-free survival. A risk-scoring model with an area under the receiver operating characteristic curve (AUC) of 0.782 (95% confidence interval 0.713–0.851) was developed in patients without missing data (n = 182). When patients with a primary refractory disease were excluded, age and blood haemoglobin concentration were identified as additional predictors of short post-recurrence survival. For this subpopulation (n = 152), a risk-scoring model with an AUC of 0.821 (95% confidence interval 0.750–0.892) was developed.ConclusionsWe report a risk-scoring model that shows acceptable to excellent accuracy in predicting post-recurrence survival in patients with endometrial carcinoma, with primary refractory diseases included or excluded. This model has potential applications in precision medicine in patients with endometrial carcinoma. |
| |
| Keywords: | Cancer recurrence Endometrial carcinoma Nomogram |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
